<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="ff61b237-be8e-461b-8114-78c52a8ad0ae"><labelDrug name="ADCIRCA"><Normalization><mmtx cui="C2709986" preferredWord="Adcirca" semType="phsu, orch"/></Normalization></labelDrug><generic name="Tadalafil"/><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1" text="Drug Label for drug brand ADCIRCA, containing Tadalafil." type="negative"><entity charOffset="46:55" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.0" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="Tadalafil." preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="26:33" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="Drug Label for drug brand ADCIRCA," preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.2" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand ADCIRCA," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.1.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4" text="&lt;item&gt;History of known serious hypersensitivity reaction to ADCIRCA or CIALIS (4.2)" type="negative"><entity charOffset="71:77" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.0" text="cialis" type="Biomedical_Entity"><Normalization><mmtx cui="C0967376" phraseText="CIALIS" preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><entity charOffset="60:67" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="to ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.4.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6" lineNumber="18" text="Do not use ADCIRCA in patients who are using any form of organic nitrate, either regularly or intermittently. " type="regular"><entity charOffset="0:10" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.0" text="Do not use" type="Caution_Interaction"/><entity charOffset="11:18" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA in patients" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="57:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.3" text="organic nitrate" type="Drug_Class"><Normalization><RxNorm RxCui="1427579"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.6.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7" lineNumber="18" text="ADCIRCA potentiates the hypotensive effect of nitrates. " type="regular"><entity charOffset="8:42" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.0" text="potentiates the hypotensive effect" type="Specific_Interaction"/><entity charOffset="46:54" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.2" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.3" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.2" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.7.e.0" type="Specific_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8" text="This potentiation is thought to result from the combined effects of nitrates and ADCIRCA on the nitric oxide/cGMP pathway see Clinical Pharmacology (12.2)." type="negative"><entity charOffset="96:108" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.0" text="nitric oxide" type="Biomedical_Entity"><Normalization><mmtx cui="C0028128" phraseText="ADCIRCA on the nitric oxide/cGMP pathway" preferredWord="Nitric Oxide" semType="bacs, inch, phsu"/><RxNorm RxCui="1311391"/></Normalization></entity><entity charOffset="81:88" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA on the nitric oxide/cGMP pathway" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.8.e.0"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10" text="ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). " type="negative"><entity charOffset="0:7" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="80:89" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="to tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="102:108" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2" text="cialis" type="Biomedical_Entity"><Normalization><mmtx cui="C0967376" phraseText="CIALIS" preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><entity charOffset="91:98" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.3" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="(ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.10.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16" lineNumber="31" text="&lt;item&gt;Concomitant alpha-blockers or alcohol: Note additive blood pressure-lowering effects. " type="irregular"><entity charOffset="50:90" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.0" text="additive blood pressure-lowering effects" type="Specific_Interaction"/><entity charOffset="18:32" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.2" text="alpha-blockers" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="&gt;Concomitant alpha-blockers" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="1023426"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.3" text="alcohol" type="Substance"><Normalization><mmtx cui="C0001975" phraseText="alcohol" preferredWord="Alcohols" semType="phsu, orch"/><RxNorm RxCui="448"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.3"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.13" text="&lt;item&gt;Cardiovascular effects: Carefully consider whether patients with certain underlying conditions (e.g., cardiovascular disease, impaired autonomic control of blood pressure, aortic stenosis) could be adversely affected by vasodilatory effects of ADCIRCA. "><entity charOffset="250:257" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.13.e.0" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="affected by vasodilatory effects of ADCIRCA." preferredWord="Adcirca" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.14" text="Not recommended in patients with pulmonary veno-occlusive disease. "/><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.15" text="(5.1)"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16.e.3"/></sentence><sentence biomedicalEntities="1" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18" lineNumber="33" text="&lt;item&gt;Use with Ritonavir: Requires dosage adjustment. " type="irregular"><entity charOffset="35:52" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18.e.0" text="dosage adjustment" type="Caution_Interaction"/><entity charOffset="15:24" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18.e.2" text="Ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="&gt;Use with Ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.18.e.2"/></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.13" text="&lt;item&gt;Cardiovascular effects: Carefully consider whether patients with certain underlying conditions (e.g., cardiovascular disease, impaired autonomic control of blood pressure, aortic stenosis) could be adversely affected by vasodilatory effects of ADCIRCA. "><entity charOffset="250:257" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.13.e.0" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="affected by vasodilatory effects of ADCIRCA." preferredWord="Adcirca" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.14" text="Not recommended in patients with pulmonary veno-occlusive disease. "/><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.15" text="(5.1)"/><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.16" text="&lt;item&gt;Concomitant alpha-blockers or alcohol: Note additive blood pressure-lowering effects. "/><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.17" text="(5.1)"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20" lineNumber="35" text="&lt;item&gt;Other concomitant potent CYP3A inhibitors: Avoid use with ADCIRCA. " type="regular"><entity charOffset="24:47" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.0" text="potent CYP3A inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="64:71" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.1" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use with ADCIRCA." preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="49:58" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.2" text="Avoid use" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.1" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.20.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22" lineNumber="37" text="&lt;item&gt;Potent Inducers of CYP3A: Avoid use of ADCIRCA in patients chronically taking potent inducers of CYP3A (e.g., rifampin). " type="regular"><entity charOffset="32:41" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.0" text="Avoid use" type="Caution_Interaction"/><entity charOffset="45:52" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="84:108" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.3" text="potent inducers of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="116:124" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.4" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.4" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.3"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.22.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28" lineNumber="43" text="&lt;item&gt;Concomitant PDE5 inhibitors: Avoid use with CIALIS or other PDE5 inhibitors. " type="irregular"><entity charOffset="35:44" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.0" text="Avoid use" type="Caution_Interaction"/><entity charOffset="50:56" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.2" text="CIALIS" type="Drug"><Normalization><mmtx cui="C0967376" phraseText="use with CIALIS" preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><entity charOffset="66:81" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.3" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="other PDE5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.3"/></relation><relation type="hasObject"><labelDrug text="ADCIRCA"/><normalization><mmtx><preferredWord>Adcirca</preferredWord><phraseText>ADCIRCA in patients</phraseText><cuiCode>C2709986</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.28.e.3"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33" text="Discuss with patients the appropriate action to take in the event that they experience anginal chest pain requiring nitroglycerin following intake of ADCIRCA. " type="negative"><entity charOffset="150:157" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="intake of ADCIRCA." preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="116:129" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.1" text="nitroglycerin" type="Biomedical_Entity"><Normalization><mmtx cui="C0885378" phraseText="anginal chest pain requiring nitroglycerin" preferredWord="Glonoine, nitroglycerine, Homeopathic preparation" semType="phsu, orch"/><RxNorm RxCui="4917"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.33.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34" lineNumber="52" text="At least 48 hours should elapse after the last dose of ADCIRCA before taking nitrates. " type="regular"><entity charOffset="55:62" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.0" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="elapse after the last dose of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="77:85" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.1" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><entity charOffset="12:51|63:76" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.2" text="hours should elapse after the last dose before taking" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.1" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.34.e.2" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35" lineNumber="52" text="If a patient has taken ADCIRCA within 48 hours, administer nitrates under close medical supervision with appropriate hemodynamic monitoring. " type="regular"><entity charOffset="23:30" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.0" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA within 48 hours," preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="59:67" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.1" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><entity charOffset="88:99" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.2" text="supervision" type="Caution_Interaction"/><entity charOffset="129:139" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.4" text="monitoring" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.ddi.2"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.1" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.35.e.2" type="Caution_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37" text="PDE5 inhibitors, including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. " type="negative"><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.0" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="27:36" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.1" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="tadalafil," preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.37.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39" text="Patients with severely impaired autonomic control of blood pressure or with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) may be particularly sensitive to the actions of vasodilators, including PDE5 inhibitors." type="negative"><entity charOffset="233:245" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="particularly sensitive to the actions of vasodilators," preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="257:272" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.1" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.39.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41" text="Since there are no clinical data on administration of ADCIRCA to patients with veno-occlusive disease, administration of ADCIRCA to such patients is not recommended. " type="negative"><entity charOffset="121:128" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="administration of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="16:32" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.1" text="no data" type="Biomedical_Entity"><Normalization><mmtx cui="C1572381" phraseText="no clinical data on administration of ADCIRCA" preferredWord="No Data re: Ingredient" semType="phsu"/><RxNorm RxCui="53704"/></Normalization></entity><entity charOffset="54:61" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.2" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="no clinical data on administration of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.41.e.2"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51" text="Use with Alpha Blockers and Antihypertensives" type="negative"><entity charOffset="28:45" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.0" text="antihypertensives" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="Antihypertensives" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="9:23" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.1" text="alpha blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0001641" phraseText="Use with Alpha Blockers" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.51.e.0"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. " type="negative"><entity charOffset="77:89" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="vasodilators with blood pressure lowering effects." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="27:34" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA," preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" text="alpha adrenergic blocking agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" lineNumber="75" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. " type="irregular"><entity charOffset="46:79" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53.e.0" text="additive effect on blood pressure" type="Specific_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" text="alpha adrenergic blocking agents" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54" lineNumber="75" text="In some patients, concomitant use of these two drug classes can lower blood pressure significantly see Clinical Pharmacology (12.2) and Drug Interactions (7.1), which may lead to symptomatic hypotension (e.g., fainting). " type="irregular"><entity charOffset="64:98" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.0" text="lower blood pressure significantly" type="Specific_Interaction"/><entity charOffset="179:202" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.2" text="symptomatic hypotension" type="Specific_Interaction"/><entity charOffset="210:218" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.4" text="fainting" type="Specific_Interaction"><Normalization><mmtx cui="C0039070" phraseText="fainting" preferredWord="Syncope" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" text="alpha adrenergic blocking agents" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.ddi.2"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" text="alpha adrenergic blocking agents" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.ddi.3"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.54.e.4"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.2" text="alpha adrenergic blocking agents" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects. "><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.52.e.0" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.53" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. "/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55" text="Safety of combined use of PDE5 inhibitors and alpha blockers may be affected by other variables, including intravascular volume depletion and use of other antihypertensive drugs see Drug Interactions (7.1)." type="negative"><entity charOffset="26:41" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.0" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="Safety of combined use of PDE5 inhibitors" preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="46:60" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.1" text="alpha blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0001641" phraseText="alpha blockers" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="155:177" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.2" text="antihypertensive drugs" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="use of other antihypertensive drugs" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.55.e.2"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57" text="Both alcohol and tadalafil are mild vasodilators. " type="negative"><entity charOffset="17:26" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.0" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="36:48" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.1" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="mild vasodilators." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.1"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.58" lineNumber="77" text="When mild vasodilators are taken in combination, blood pressure-lowering effects are increased see Drug Interactions (7.1) and Clinical Pharmacology (12.2)." type="irregular"><entity charOffset="49:94" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.58.e.0" text="blood pressure-lowering effects are increased" type="Specific_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.58.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.58.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57" text="Both alcohol and tadalafil are mild vasodilators. "><entity charOffset="17:26" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.1" text="tadalafil" type="Drug"><Normalization><mmtx cui="C1176316" phraseText="tadalafil" preferredWord="tadalafil" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57" text="Both alcohol and tadalafil are mild vasodilators. "><entity charOffset="5:12" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.57.e.0" text="alcohol" type="Substance"><Normalization><mmtx cui="C0001975" phraseText="Both alcohol" preferredWord="Alcohols" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60" text="Co-administration of ADCIRCA in Patients on Ritonavir" type="negative"><entity charOffset="44:53" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.0" text="ritonavir" type="Biomedical_Entity"><Normalization><mmtx cui="C0292818" phraseText="on Ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="21:28" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="Co-administration of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.60.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61" lineNumber="82" text="In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. " type="regular"><entity charOffset="55:60|69:71|75:88" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.0" text="start at mg once daily" type="Caution_Interaction"/><entity charOffset="61:68" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="start ADCIRCA at 20 mg once daily." preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="22:31" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.3" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="ritonavir for" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.2" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.62" lineNumber="82" text="Increase to 40 mg once daily based upon individual tolerability see Dosage and Administration (2.3), Drug Interactions (7.2) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:11|15:63" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.62.e.0" text="Increase to mg once daily based upon individual tolerability" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.62.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.62.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61" text="In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. "><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.3"/></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61" text="In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. "><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.61.e.2"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63" text="Co-administration of Ritonavir in Patients on ADCIRCA" type="negative"><entity charOffset="46:53" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="on ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="21:30" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.1" text="ritonavir" type="Biomedical_Entity"><Normalization><mmtx cui="C0292818" phraseText="Co-administration of Ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.63.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64" lineNumber="84" text="Avoid use of ADCIRCA during the initiation of ritonavir. " type="regular"><entity charOffset="0:9|21:42" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.0" text="Avoid use during the initiation" type="Caution_Interaction"/><entity charOffset="46:55" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.2" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="of ritonavir." preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="13:20" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.3" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.2" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.64.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65" lineNumber="84" text="Stop ADCIRCA at least 24 hours prior to starting ritonavir. " type="regular"><entity charOffset="0:4|25:48" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.0" text="Stop hours prior to starting" type="Caution_Interaction"/><entity charOffset="5:12" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="Stop ADCIRCA at least 24 hours" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="49:58" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.3" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="prior to starting ritonavir." preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.65.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66" lineNumber="84" text="After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. " type="regular"><entity charOffset="63:69" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.0" text="resume" type="Caution_Interaction"/><entity charOffset="52:61" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.2" text="ritonavir" type="Drug"><Normalization><mmtx cui="C0292818" phraseText="the initiation of ritonavir," preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="70:77" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.3" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="resume ADCIRCA at 20 mg once daily." preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.67" lineNumber="84" text="Increase to 40 mg once daily based upon individual tolerability see Dosage and Administration (2.3), Drug Interactions (7.2) and Clinical Pharmacology (12.3)." type="irregular"><entity charOffset="0:11|15:63" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.67.e.0" text="Increase to mg once daily based upon individual tolerability" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.67.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.67.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66" text="After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. "><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.2"/></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66" text="After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. "><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.66.e.3"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="4" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70" lineNumber="86" text="In patients taking potent inhibitors of CYP3A such as ketoconazole and itraconazole, avoid use of ADCIRCA see Drug Interactions (7.2) and Clinical Pharmacology (12.3)." type="regular"><entity charOffset="85:94" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.0" text="avoid use" type="Caution_Interaction"/><entity charOffset="98:105" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="19:45" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3" text="potent inhibitors of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="54:66" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.4" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="such as ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="71:83" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.5" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.4" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3"/><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.5" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.2" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.70.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72" lineNumber="88" text="For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of ADCIRCA see Drug Interactions (7.2) and Clinical Pharmacology (12.3)." type="regular"><entity charOffset="32:56" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.0" text="potent inducers of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="66:74" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="such as rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="76:85" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.3" text="avoid use" type="Caution_Interaction"/><entity charOffset="89:96" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.5" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.1" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.0"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.3"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.5" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.72.e.3" type="Caution_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78" text="Avoid use of ADCIRCA because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)." type="negative"><entity charOffset="13:20" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="42:51" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.1" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="because of increased tadalafil exposure" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.78.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89" text="Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators such as PDE5 inhibitors see Adverse Reactions (6.2)." type="negative"><entity charOffset="229:244" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.0" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="such as PDE5 inhibitors" preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="208:220" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.1" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="affected by use of vasodilators" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.89.e.0"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93" text="These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including ADCIRCA. " type="negative"><entity charOffset="153:160" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA." preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="126:141" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.1" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="of PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.93.e.0"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96" text="Tadalafil is also marketed as CIALIS. " type="negative"><entity charOffset="30:36" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.0" text="cialis" type="Biomedical_Entity"><Normalization><mmtx cui="C0967376" phraseText="marketed as CIALIS." preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.1" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="Tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.96.e.0"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97" text="The safety and efficacy of taking ADCIRCA together with CIALIS or other PDE5 inhibitors have not been studied. " type="negative"><entity charOffset="34:41" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.0" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="efficacy of taking ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="72:87" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.1" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="other PDE5 inhibitors" preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="56:62" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.2" text="cialis" type="Biomedical_Entity"><Normalization><mmtx cui="C0967376" phraseText="together with CIALIS" preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.97.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98" lineNumber="115" text="Inform patients taking ADCIRCA not to take CIALIS or other PDE5 inhibitors." type="regular"><entity charOffset="31:42" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.0" text="not to take" type="Caution_Interaction"/><entity charOffset="23:30" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="43:49" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3" text="CIALIS" type="Drug"><Normalization><mmtx cui="C0967376" phraseText="CIALIS" preferredWord="Cialis" semType="phsu, orch"/><RxNorm RxCui="303263"/></Normalization></entity><entity charOffset="59:74" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="other PDE5 inhibitors." preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.98.e.4"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106" text="When administered in combination with aspirin, tadalafil 20 mg did not prolong bleeding time, relative to aspirin alone. " type="negative"><entity charOffset="106:113" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.0" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="relative to aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="38:45" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="with aspirin," preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><entity charOffset="47:62" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.2" text="tadalafil 20 mg" type="Biomedical_Entity"><Normalization><mmtx cui="C1321753" phraseText="tadalafil 20 mg" preferredWord="tadalafil 20 MG" semType="clnd"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.106.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112" lineNumber="133" text="Do not use ADCIRCA in patients who are using any form of organic nitrate see Contraindications (4.1). " type="regular"><entity charOffset="0:10" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.0" text="Do not use" type="Caution_Interaction"/><entity charOffset="11:18" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA in patients" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="57:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.3" text="organic nitrate" type="Drug_Class"><Normalization><RxNorm RxCui="1427579"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.112.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113" lineNumber="133" text="In clinical pharmacology studies ADCIRCA potentiated the hypotensive effect of nitrates see Clinical Pharmacology (12.2). " type="regular"><entity charOffset="41:75" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.0" text="potentiated the hypotensive effect" type="Specific_Interaction"/><entity charOffset="33:40" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="79:87" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.3" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.113.e.0" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114" lineNumber="133" text="In a patient who has taken ADCIRCA, where nitrate administration is deemed medically necessary in a life threatening situation, at least 48 hours should elapse after the last dose of ADCIRCA before nitrate administration is considered. " type="regular"><entity charOffset="140:179" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.0" text="hours should elapse after the last dose" type="Caution_Interaction"/><entity charOffset="183:190" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.2" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="elapse after the last dose of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="198:205" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.3" text="nitrate" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.3" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115" lineNumber="133" text="In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring." type="irregular"><entity charOffset="86:97" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.0" text="supervision" type="Caution_Interaction"/><entity charOffset="23:31" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.2" text="nitrates" type="Drug_Class"><Normalization><RxNorm RxCui="202927"/></Normalization></entity><entity charOffset="127:137" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.3" text="monitoring" type="Caution_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114" text="In a patient who has taken ADCIRCA, where nitrate administration is deemed medically necessary in a life threatening situation, at least 48 hours should elapse after the last dose of ADCIRCA before nitrate administration is considered. "><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.114.e.2"/></ellipsisSentence></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.2"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.ddi.2"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.3"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.115.e.2"/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. " type="negative"><entity charOffset="82:94" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="both vasodilators with blood-pressure-lowering effects." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="27:34" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA," preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3" text="alpha adrenergic blocking agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.3"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.118" lineNumber="135" text="When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. " type="irregular"><entity charOffset="46:79" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.118.e.0" text="additive effect on blood pressure" type="Specific_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.118.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.118.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. "><entity charOffset="40:72" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.2" text="alpha adrenergic blocking agents" type="Drug_Class"><Normalization><mmtx cui="C0001641" phraseText="alpha adrenergic blocking agents" preferredWord="Adrenergic alpha-Antagonists" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117" text="PDE5 inhibitors, including ADCIRCA, and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. "><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.117.e.0" text="PDE5 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119" text="Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)." type="negative"><entity charOffset="114:124" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0" text="tamsulosin" type="Biomedical_Entity"><Normalization><mmtx cui="C0257343" phraseText="tamsulosin" preferredWord="tamsulosin" semType="phsu, orch"/><RxNorm RxCui="77492"/></Normalization></entity><entity charOffset="101:110" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1" text="alfuzosin" type="Biomedical_Entity"><Normalization><mmtx cui="C0051150" phraseText="alfuzosin" preferredWord="alfuzosin" semType="phsu, orch"/><RxNorm RxCui="46043"/></Normalization></entity><entity charOffset="90:99" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2" text="doxazosin" type="Biomedical_Entity"><Normalization><mmtx cui="C0114873" phraseText="with doxazosin," preferredWord="Doxazosin" semType="phsu, orch"/><RxNorm RxCui="39173"/></Normalization></entity><entity charOffset="75:84" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="conducted with coadministration of tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.119.e.2"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121" text="PDE5 inhibitors, including ADCIRCA, are mild systemic vasodilators. " type="negative"><entity charOffset="54:66" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="mild systemic vasodilators." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="27:34" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.1" text="adcirca" type="Biomedical_Entity"><Normalization><mmtx cui="C2709986" phraseText="ADCIRCA," preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="0:15" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.2" text="pde5 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="PDE5 inhibitors," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.121.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). " type="negative"><entity charOffset="262:272" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0" text="metoprolol" type="Biomedical_Entity"><Normalization><mmtx cui="C0025859" phraseText="metoprolol" preferredWord="Metoprolol" semType="phsu, orch"/><RxNorm RxCui="6918"/></Normalization></entity><entity charOffset="180:190" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="(amlodipine," preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="192:224" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2" text="angiotensin ii receptor blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0521942" phraseText="angiotensin II receptor blockers," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="226:245" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3" text="bendroflumethiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0004975" phraseText="bendroflumethiazide," preferredWord="Bendroflumethiazide" semType="phsu, orch"/><RxNorm RxCui="1369"/></Normalization></entity><entity charOffset="150:166" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="of selected antihypertensive medications" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="69:78" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="the effect of tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="247:256" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6" text="enalapril" type="Biomedical_Entity"><Normalization><mmtx cui="C0014025" phraseText="enalapril," preferredWord="Enalapril" semType="phsu, aapp"/><RxNorm RxCui="203123"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.6"/></sentence><sentence biomedicalEntities="1" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123" lineNumber="137" text="Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)." type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" Text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). "/><anaphoraEntity charOffset="89:101" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" text="these agents" type="Expression"/><antecedentEntity charOffset="180:190" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.0" text="amlodipine" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" Text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). "/><anaphoraEntity charOffset="89:101" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" text="these agents" type="Expression"/><antecedentEntity charOffset="192:224" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.1" text="angiotensin II receptor blockers" type="Drug_Class"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" Text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). "/><anaphoraEntity charOffset="89:101" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" text="these agents" type="Expression"/><antecedentEntity charOffset="226:245" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.3" text="bendroflumethiazide" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" Text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). "/><anaphoraEntity charOffset="89:101" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" text="these agents" type="Expression"/><antecedentEntity charOffset="247:256" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.4" text="enalapril" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122" Text="Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). "/><anaphoraEntity charOffset="89:101" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" text="these agents" type="Expression"/><antecedentEntity charOffset="262:272" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.122.e.5" text="metoprolol" type="Drug"/></anaphoraRelation><entity charOffset="0:34" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.0" text="Small reductions in blood pressure" type="Specific_Interaction"/><entity charOffset="74:83" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.8" text="tadalafil" type="Drug"><Normalization><mmtx cui="C1176316" phraseText="coadministration of tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.8"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.8" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.2" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.123.e.0" type="Specific_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125" text="Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. " type="negative"><entity charOffset="58:70" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="act as mild vasodilators." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="30:44" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1" text="pde5 inhibitor" type="Biomedical_Entity"><Normalization><mmtx cui="C1318700" phraseText="a PDE5 inhibitor," preferredWord="Phosphodiesterase 5 inhibitor" semType="phsu"/><RxNorm RxCui="230032"/></Normalization></entity><entity charOffset="17:26" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.2" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="tadalafil," preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1"/></sentence><sentence biomedicalEntities="0" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.126" lineNumber="139" text="When mild vasodilators are taken in combination, blood pressure lowering effects of each individual compound may be increased. " type="irregular"><entity charOffset="49:125" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.126.e.0" text="blood pressure lowering effects of each individual compound may be increased" type="Specific_Interaction"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.126.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.126.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125" text="Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. "><entity charOffset="5:12" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.1" text="alcohol" type="Substance"><Normalization><mmtx cui="C0001975" phraseText="Both alcohol" preferredWord="Alcohols" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125" text="Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. "><entity charOffset="17:26" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.125.e.0" text="tadalafil" type="Drug"><Normalization><mmtx cui="C1176316" phraseText="tadalafil," preferredWord="tadalafil" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="2" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127" lineNumber="139" text="Substantial consumption of alcohol (e.g., 5 units or greater) in combination with ADCIRCA can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. " type="regular"><entity charOffset="27:34" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0" text="alcohol" type="Substance"><Normalization><mmtx cui="C0001975" phraseText="Substantial consumption of alcohol" preferredWord="Alcohols" semType="phsu, orch"/><RxNorm RxCui="448"/></Normalization></entity><entity charOffset="82:89" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="with ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><entity charOffset="121:151" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.2" text="orthostatic signs and symptoms" type="Specific_Interaction"><Normalization><mmtx cui="C0149746" phraseText="the potential for orthostatic signs" preferredWord="Orthostasis" semType="sosy"/><mmtx cui="C1457887" phraseText="symptoms," preferredWord="Symptoms" semType="sosy"/></Normalization></entity><entity charOffset="163:185" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.4" text="increase in heart rate" type="Specific_Interaction"/><entity charOffset="187:222" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.6" text="decrease in standing blood pressure" type="Specific_Interaction"/><entity charOffset="224:233" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.8" text="dizziness" type="Specific_Interaction"><Normalization><mmtx cui="C0012833" phraseText="dizziness," preferredWord="Dizziness" semType="sosy"/><mmtx cui="C0042571" phraseText="dizziness," preferredWord="Vertigo" semType="sosy"/></Normalization></entity><entity charOffset="239:247" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.10" text="headache" type="Specific_Interaction"><Normalization><mmtx cui="C0018681" phraseText="headache." preferredWord="Headache" semType="sosy"/></Normalization></entity><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.ddi.2"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.ddi.3"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.ddi.4"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.8"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.ddi.5"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.10"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.1" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.127.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132" text="Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. " type="negative"><entity charOffset="0:9" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.0" text="ritonavir" type="Biomedical_Entity"><Normalization><mmtx cui="C0292818" phraseText="Ritonavir initially" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="95:104" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.1" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="involved in the metabolism of tadalafil." preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.132.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133" text="At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir see Dosage and Administration (2.3), Warnings and Precautions (5.2), and Clinical Pharmacology (12.3)." type="negative"><entity charOffset="61:70" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.0" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="the exposure to tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="103:112" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.1" text="ritonavir" type="Biomedical_Entity"><Normalization><mmtx cui="C0292818" phraseText="as in the absence of ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><entity charOffset="19:28" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.2" text="ritonavir" type="Biomedical_Entity"><Normalization><mmtx cui="C0292818" phraseText="of ritonavir" preferredWord="Ritonavir" semType="phsu, orch"/><RxNorm RxCui="85762"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.133.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135" lineNumber="145" text="In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of ADCIRCA see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)." type="regular"><entity charOffset="19:45" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.0" text="potent inhibitors of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="54:66" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.1" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="such as ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="72:84" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.2" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="86:95" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.5" text="avoid use" type="Caution_Interaction"/><entity charOffset="99:106" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.7" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.1" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.0"/><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.2" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.0"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.5"><relations><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.135.e.7"/></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="3" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136" lineNumber="146" text="For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of ADCIRCA see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)." type="regular"><entity charOffset="32:56" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.0" text="potent inducers of CYP3A" type="Drug_Class"><Normalization><RxNorm RxCui="402226"/></Normalization></entity><entity charOffset="66:74" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="such as rifampin," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="76:85" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.3" text="avoid use" type="Caution_Interaction"/><entity charOffset="89:96" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.5" text="ADCIRCA" type="Drug"><Normalization><mmtx cui="C2709986" phraseText="use of ADCIRCA" preferredWord="Adcirca" semType="phsu, orch"/><RxNorm RxCui="849863"/></Normalization></entity><drugClassMembership drug="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.1" drugClass="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.0"/><drugInteraction id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.ddi.1"><interaction trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.5" trigger="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.136.e.3" type="Caution_Interaction"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139" text="Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms (e.g., theophylline, warfarin, midazolam, lovastatin, bosentan) see Clinical Pharmacology (12.3)." type="negative"><entity charOffset="161:173" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0" text="theophylline" type="Biomedical_Entity"><Normalization><mmtx cui="C0039771" phraseText="theophylline," preferredWord="Theophylline" semType="bacs, phsu, orch"/><RxNorm RxCui="10438"/></Normalization></entity><entity charOffset="208:216" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="Tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="185:194" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3" text="midazolam" type="Biomedical_Entity"><Normalization><mmtx cui="C0026056" phraseText="midazolam," preferredWord="Midazolam" semType="phsu, orch"/><RxNorm RxCui="203128"/></Normalization></entity><entity charOffset="196:206" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4" text="lovastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0024027" phraseText="lovastatin," preferredWord="Lovastatin" semType="phsu, orch"/><RxNorm RxCui="6472"/></Normalization></entity><entity charOffset="175:183" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin," preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.1"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.2" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.3"/><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.5" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.139.e.4"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141" text="Tadalafil (10 mg and 20 mg once daily) does not potentiate the increase in bleeding time caused by aspirin see Clinical Pharmacology (12.3)." type="negative"><entity charOffset="0:9" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.0" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="Tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="99:106" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.1" text="aspirin" type="Biomedical_Entity"><Normalization><mmtx cui="C0004057" phraseText="caused by aspirin" preferredWord="Aspirin" semType="phsu, orch"/><RxNorm RxCui="1191"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.141.e.1"/></sentence><sentence id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143" text="Coadministration of tadalafil (40 mg once daily) for 10 days did not significantly alter digoxin pharmacokinetics in healthy subjects see Clinical Pharmacology (12.3)." type="negative"><entity charOffset="20:29" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.0" text="tadalafil" type="Biomedical_Entity"><Normalization><mmtx cui="C1176316" phraseText="Coadministration of tadalafil" preferredWord="tadalafil" semType="phsu, orch"/><RxNorm RxCui="358263"/></Normalization></entity><entity charOffset="89:96" id="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.1" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="digoxin pharmacokinetics in healthy subjects" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><pair ddi="false" e1="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.0" e2="Dailymed.ff61b237-be8e-461b-8114-78c52a8ad0ae.s.143.e.1"/></sentence><positiveExamples number="24"/><negativeExamples number="99"/></document>